<?xml version='1.0' encoding='utf-8'?>
<document id="25268386"><sentence text="Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers."><entity charOffset="99-109" id="DDI-PubMed.25268386.s1.e0" text="metoprolol" /></sentence><sentence text="1" /><sentence text=" Recently, we demonstrated that sarpogrelate is a potent and selective CYP2D6 inhibitor in vitro" /><sentence text=" Here, we evaluated the effect of sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy subjects"><entity charOffset="95-105" id="DDI-PubMed.25268386.s4.e0" text="metoprolol" /></sentence><sentence text=" 2" /><sentence text=" Nine healthy male subjects genotyped for CYP2D6*1/*1 or *1/*2 were included in an open-label, randomized, three treatment-period and crossover study" /><sentence text=" A single oral dose of metoprolol (100 mg) was administered with water (treatment A) and sarpogrelate (100 mg bid"><entity charOffset="23-33" id="DDI-PubMed.25268386.s7.e0" text="metoprolol" /></sentence><sentence text="; a total dose of 200 mg and treatment B), or after pretreatment of sarpogrelate for three days (100 mg tid" /><sentence text="; treatment C)" /><sentence text=" Plasma levels of metoprolol and α-hydroxymetoprolol were determined using a validated LC-MS/MS method"><entity charOffset="18-28" id="DDI-PubMed.25268386.s10.e0" text="metoprolol" /><entity charOffset="33-52" id="DDI-PubMed.25268386.s10.e1" text="α-hydroxymetoprolol" /><pair ddi="false" e1="DDI-PubMed.25268386.s10.e0" e2="DDI-PubMed.25268386.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25268386.s10.e0" e2="DDI-PubMed.25268386.s10.e1" /></sentence><sentence text=" Changes in heart rate and blood pressure were monitored as pharmacodynamic responses to metoprolol"><entity charOffset="89-99" id="DDI-PubMed.25268386.s11.e0" text="metoprolol" /></sentence><sentence text=" 3" /><sentence text=" Metoprolol was well tolerated in the three treatment groups"><entity charOffset="1-11" id="DDI-PubMed.25268386.s13.e0" text="Metoprolol" /></sentence><sentence text=" In treatment B and C groups, the AUCt of metoprolol increased by 53% (GMR, 1"><entity charOffset="42-52" id="DDI-PubMed.25268386.s14.e0" text="metoprolol" /></sentence><sentence text="53; 90% CI, 1" /><sentence text="17-2" /><sentence text="31) and by 51% (1" /><sentence text="51; 1" /><sentence text="17-2" /><sentence text="31), respectively" /><sentence text=" Similar patterns were observed for the increase in Cmax of metoprolol by sarpogrelate"><entity charOffset="60-70" id="DDI-PubMed.25268386.s21.e0" text="metoprolol" /></sentence><sentence text=" However, the pharmacodynamics of metoprolol did not differ significantly among the three treatment groups"><entity charOffset="34-44" id="DDI-PubMed.25268386.s22.e0" text="metoprolol" /></sentence><sentence text=" 4" /><sentence text=" Greater systemic exposure to metoprolol after co-administration or pretreatment with sarpogrelate did not result in clinically relevant effects"><entity charOffset="30-40" id="DDI-PubMed.25268386.s24.e0" text="metoprolol" /></sentence><sentence text=" Co-administration of both agents is well tolerated and can be employed without the need for dose adjustments" /><sentence text="" /></document>